P-296 - Preventive intraperitoneal chemotherapy in colon cancers with high risk of recurrence: outcome at 5 years from a prospective study

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Presenter M. Abid
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M. Abid
  • Centre Anti-Cancer Batna, Batna/DZ

Abstract

Introduction

The study evaluated the effectiveness of adjuvant immediate postoperative intraperitoneal chemotherapy (IPIPC), in the prevention of local and peritoneal recurrence in colon cancer at high risk of recurrence and the 5-year survival.

Methods

After surgical resection, 105 patients considered in preoperative or intraoperative period at high risk of peritoneal recurrence (CT3/T4, tumor perforation, localized carcinomatosis, ovarian damage, bowel obstruction, positive extemporaneous intraoperative cytology) were randomized after radical surgical resection in two groups. The first group (n = 53) received from postoperative D1 to D5, intraperitoneal chemotherapy with mitomycin C (D0: 10 to 15 mg/m2) and 5-fluorouracil (D1 - D4: 650 mg/m2). In the second group (n = 52), only curative surgical resection was performed.

Results

Local or peritoneal recurrence has been observed in 4 cases (7.6%) in the group whom received intraperitoneal chemotherapy against 14 cases (26.9%) in the second group (p = 0. 008 s). In the postoperative period, ranging from D0 to D30, 7 patients died within the two groups. Immediate intraperitoneal chemotherapy was associated with a mortality 3 times higher than for the control group: 5 patients (9.4%) in the group treated with intraperitoneal chemotherapy against 2 patients (3.8%) in the control group. This difference was not significant (P = 0, 25 ns). The 5-year survival is about 54.7 months for Group 1 against 48.7 months in the control group (P = 0. 812 ns).

Conclusion

In this study, adjuvant intraperitoneal chemotherapy in colon cancer with high risk of recurrence has led a significant reduction in the rate of local and peritoneal recurrence but doesn't really increase the 5-year survival.